New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTTLYS, BURL, GSK, DDD, CIDM, LEN, FSLR, XONE, BGMD, SNTA, SSYS, GESOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 17, 2014
13:12 EDTDDD, SSYS3D Systems rises after insider buy, Voxeljet slips after downgrade
Subscribe for More Information
11:35 EDTFSLRStocks with call strike movement; GNW FLSR
Genworth (GNW) March 11 call option implied volatility increased 6% to 53, First Solar (FSLR) March 55 call option implied volatility increased 12% to 51 according to IVolatility.
10:38 EDTSSYSStratasys announces partnership with Martha Stewart Living Omnimedia
Subscribe for More Information
09:59 EDTFSLRFirst Solar calls active on renewed takeover speculation
Subscribe for More Information
09:57 EDTDDD3D Systems up 3.5% in early trading following Chairman stock purchase
Subscribe for More Information
09:46 EDTFSLRRumor: First Solar strength attributed to renewed takeover speculation
Subscribe for More Information
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
November 14, 2014
14:53 EDTGSKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:10 EDTDDDOptions with decreasing implied volatility
Subscribe for More Information
08:33 EDTXONEExOne momentum may improve in 2015, says Oppenheimer
After ExOne reported weaker than expected Q3 results, Oppenheimer says the company was confident that its performance will improve in Q4. The firm thinks that ExOne's 2015 guidance looks conservative, while the company's momentum may improve significantly in 6-12 months. It keeps an Outperform rating on the shares.
08:20 EDTXONEExOne price target lowered to $37 from $45 at FBR Capital
FBR Capital lowered its price target for ExOne shares to $37 saying deferrals impacted the company's Q3 results. The firm keeps an Outperform rating on the stock.
07:14 EDTGSKAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
16:10 EDTCIDMCinedigm reports Q2 continued operations EPS (6c), consensus (9c)
Subscribe for More Information
13:17 EDTSSYSMakerBot acquires Layer by Layer, terms not disclosed
MakerBot, a subsidiary of Stratasys, announced the acquisition of the start-up software company Layer By Layer. The goal of the acquisition of Layer By Layer is to help accelerate MakerBot’s position in the entertainment and 3D printing management spaces, as part of its effort to build a more robust 3D ecosystem.
12:59 EDTGSKApollo plans bid for GSK mature drugs business, Reuters reports
Subscribe for More Information
10:57 EDTBGMDBG Medicine downgraded to Neutral from Buy at Ladenburg
Ladenburg downgraded BG Medicine to Neutral citing valuation following the company's Q3 results.
10:44 EDTFSLROptions with decreasing implied volatility
Subscribe for More Information
07:18 EDTLENUBS to hold a conference
Building & Building Products Annual CEO Conference is being held in New York on November 13 with webcasted company presentations to begin at 9:30 am; not all company presentations may be webcasted. Webcast Link
06:33 EDTBGMDBG Medicine sees 2014 revenue $2.8M-$3.0M, one estimate $3.10M
Subscribe for More Information
06:32 EDTBGMDBG Medicine reports Q3 EPS (7c), one estimate (7c)
Reports Q3 revenue $695K, one estimate $800.00K.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use